Digital Therapeutic Lifestyle Intervention Program for Patients With MASLD

Exclusion Criteria

• •1. Recent (within 3 mos. of SV) participation in lifestyle intervention program or use of supplements marked for weight loss or appetite.
• •2. Plans to undergo bariatric surgery or initiate anti-obesity medication.
• •3. History of cirrhosis and/or hepatic decompensation (e.g., ascites, encephalopathy, variceal bleeding)
• •4. Liver disease of other etiologies (e.g., viral hepatitis), including liver transplantation
• •5. History of excessive alcohol consumption defined by self-report (men \>30g/d or women \>20g/d), AUDIT-C \>4 or PETH \> 20ug/L
• •6. History of malignancy within last 5 yrs., excluding successful treatment of non-melanoma skin cancer
• •7. Participant in any clinical trial or use of drugs under investigation for treatment of MASH within 3 mos. of SV
• •8. History of type 1 diabetes or uncontrolled type 2 diabetes (A1c \>9.5% or changes in diabetes medication doses within 3 mos. of SV)
• •9. Recent (within 3 mos. of SV) initiation or change in dose of medications used to treat MASH (e.g., vitamin E, pioglitazone)
• •10. Recent (within 3 mos. of SV) use of drugs associated with the development of steatotic liver disease (e.g., methotrexate, tamoxifen)
• •11. Known or suspected history of drug abuse within the last 2 years prior to SV at the discretion of study investigator
• •12. Vulnerable participants (e.g., protected adults under guardianship or committed to an institution by governmental or judicial order)
• •13. Participants who cannot communicate with the study investigators or use digital technology reliably
• •14. Severe medical comorbidities that may hinder study participation at the discretion of study investigator
• •15. Current pregnancy or plans to become pregnant during the study period